Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, announced today that breast cancer drugs typically used in later stages of the disease will be used in early stages of the disease as well. The report, entitled Breast Cancer, also found that tamoxifen will see major competition from a new group of agents.

(Photo: )

"Widely-used tamoxifen has enjoyed market dominance in the treatment of early stage breast cancer," said Sarah Simnett, analyst, Decision Resources. "However, our findings indicate that a new group of agents are poised to take over tamoxifen's leading position. Third generation aromatase inhibitors are more effective and less toxic than older aromatase inhibitors, allowing them to compete with tamoxifen in the treatment market for early-stage breast cancer. For example, AstraZeneca's Arimidex (anastrozole) has shown lower relapse rates than tamoxifen."

Disease Facts - Breast Cancer

Breast cancer is the most common cancer in women and the second most common cause of malignancy-related death. Although incidence of breast cancer is rising in the seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan), primarily because of the growing number of elderly women, more women are surviving the disease and those that are not cured are living longer.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Diseases, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Breast Cancer is an Onkos report.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,

New Report Finds That HMO Enrollment Continues To Decline

View Now